Identification of ZCCHC8 as fusion partner of ROS1 in a case of congenital glioblastoma multiforme with a t(6;12)(q21;q24.3)

Congenital gliobastoma multiforme (GBM) is rare and little is known about the molecular defects underlying the initiation and progression of this tumor type. We present a case of congenital GBM analyzed by conventional cytogenetics, fluorescence in situ hybridization, array comparative genomic hybridization and next generation sequencing. On cytogenetic analysis we detected a reciprocal translocation t(6;12)(q21;q24.3). By sequencing, the translocation was shown to form a fusion between the 5′ region of ZCCHC8 and the 3′ region of ROS1. RT‐PCR analyses confirmed the existence of an in‐frame fusion transcript with ZCCHC8 exons 1‐3 joined to ROS1 exons 36‐43. In addition to the ZCCHC8‐ROS1 fusion, we detected a deletion in the short arm of chromosome 9, including homozygous loss of the CDKN2A/2B locus in 9p21.3 and heterozygous deletion of the HAUS6 gene in 9p22.1. The latter encodes a protein involved in faithful chromosome segregation by regulating microtubule nucleation and its deletion might be associated with the marked subclonal changes of ploidy observed in the tumor. This report adds the ZCCHC8‐ROS1 fusion as oncogenic driver in GBM and supports the role of ROS1 activation in the pathogenesis of a subset of GBM. © 2016 Wiley Periodicals, Inc.

[1]  S. Ren,et al.  Coexistence of Three Variants Involving Two Different Fusion Partners of ROS1 Including a Novel Variant of ROS1 Fusions in Lung Adenocarcinoma: A Case Report , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  Iwei Yeh,et al.  Kinase fusions are frequent in Spitz tumours and spitzoid melanomas , 2014, Nature Communications.

[3]  V. Beneš,et al.  Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. , 2013, Cancer cell.

[4]  Kenny Q. Ye,et al.  An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.

[5]  Thomas Zichner,et al.  DELLY: structural variant discovery by integrated paired-end and split-read analysis , 2012, Bioinform..

[6]  B. Kleinschmidt-DeMasters,et al.  Clinical and molecular characteristics of congenital glioblastoma. , 2012, Neuro-oncology.

[7]  T. Gu,et al.  Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion , 2012, Clinical Cancer Research.

[8]  C. Greenwood,et al.  Chromosome 3 Anomalies Investigated by Genome Wide SNP Analysis of Benign, Low Malignant Potential and Low Grade Ovarian Serous Tumours , 2011, PloS one.

[9]  B. Manoranjan,et al.  Congenital Brain Tumors: Diagnostic Pitfalls and Therapeutic Interventions , 2011, Journal of child neurology.

[10]  Jian Yu,et al.  Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma , 2011, PloS one.

[11]  G. Goshima,et al.  The augmin complex plays a critical role in spindle microtubule generation for mitotic progression and cytokinesis in human cells , 2009, Proceedings of the National Academy of Sciences.

[12]  Darell D. Bigner,et al.  Glioblastoma Multiforme Oncogenomics and Signaling Pathways , 2009, Clinical medicine. Oncology.

[13]  Philip M. Kim,et al.  Paired-End Mapping Reveals Extensive Structural Variation in the Human Genome , 2007, Science.

[14]  D. Brat,et al.  Congenital Glioblastoma: A Clinicopathologic and Genetic Analysis , 2007, Brain pathology.

[15]  Aşkın Şeker,et al.  Congenital glioblastoma multiforme. Case report and review of the literature. , 2006, Journal of neurosurgery.

[16]  Keara M. Lane,et al.  ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. , 2006, Cancer research.

[17]  P. Kleihues,et al.  Epidemiology and etiology of gliomas , 2005, Acta Neuropathologica.

[18]  Paola Pisani,et al.  Genetic Pathways to Glioblastoma , 2004, Cancer Research.

[19]  Keara M. Lane,et al.  Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21) , 2003, Genes, chromosomes & cancer.

[20]  D. Davis,et al.  Congenital glioblastoma multiforme: a report of three cases and a review of the literature , 2001, Journal of the Neurological Sciences.

[21]  W. Paulus,et al.  Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification , 2001, Child’s Nervous System.

[22]  Douglas C. Miller,et al.  Preferential Inactivation of the p53 Tumor Suppressor Pathway and Lack of EGFR Amplification Distinguish de novo High Grade Pediatric Astrocytomas from de novo Adult Astrocytomas , 2000, Brain pathology.

[23]  C. James,et al.  Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  E. Macintyre,et al.  Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease , 1999, Leukemia.

[25]  W. Poon,et al.  Genetic alterations in pediatric high-grade astrocytomas. , 1999, Human pathology.

[26]  C. James,et al.  Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  G. Basso,et al.  Cytogenetics of pediatric central nervous system tumors. , 1996, Cancer genetics and cytogenetics.

[28]  K. Mrózek,et al.  Accumulation of chromosomal changes in human glioma progression. A cytogenetic study of 50 cases. , 1995, Cancer genetics and cytogenetics.

[29]  J. Malone,et al.  Chromosomal abnormalities in 47 pediatric brain tumors. , 1995, Cancer genetics and cytogenetics.

[30]  D. Louis,et al.  Human gliomas with wild-type p53 express bcl-2. , 1995, Cancer research.

[31]  D. Louis.  The p53 Gene and Protein in Human Brain Tumors , 1994, Journal of neuropathology and experimental neurology.

[32]  S. Wakai,et al.  Congenital brain tumors. , 1984, Surgical neurology.

[33]  M. Krigman,et al.  CONGENITAL INTRACRANIAL NEOPLASM , 1964 .

[34]  E. Boldrey,et al.  A case report and survey of brain tumors during the neonatal period. , 1951, Journal of neurosurgery.

[35]  R. Doebele,et al.  Molecular Pathways Molecular Pathways : ROS 1 Fusion Proteins in Cancer , 2013 .

[36]  L. Shaffer,et al.  ISCN 2009 - An International System for Human Cytogenetic Nomenclature , 2009 .

[37]  Cdm Fletcher,et al.  World Health Organization Classification of Tumours , 2002 .

[38]  Webster K. Cavenee,et al.  Pathology and genetics of tumours of the nervous system. , 2000 .

[39]  P. Kleihues,et al.  Primary and secondary glioblastomas: from concept to clinical diagnosis. , 1999, Neuro-oncology.

[40]  D. C. Henckel,et al.  Case report. , 1995, Journal.

[41]  M. Tsuda.  [Chromosomal abnormalities]. , 1995, Ryoikibetsu shokogun shirizu.

[42]  M. Jain,et al.  Congenital glioblastoma , 1994, Indian journal of pediatrics.

[43]  H. Schmetzer,et al.  Minimal residual disease in acute leukemia. , 1991, European journal of cancer.

[44]  M. Krigman,et al.  CONGENITAL INTRACRANIAL NEOPLASM. A CASE REPORT AND REVIEW OF THE LITERATURE. , 1964, Journal of neuropathology and experimental neurology.

[45]  I. Pollack,et al.  The Relationship between TPS 3 Mutations and Overexpression of p 53 and Prognosis in Malignant Gliomas of Childhood ' , 2022 .